Experienced in Muscle Invasive Bladder Cancer

Dr. Sanjay Maraboyina

Radiation Oncology
University Of Arkansas For Medical Sciences
1 Childrens Way, Suite 653, 
Little Rock, AR 
Accepting New Patients
Offers Telehealth
Experienced in Muscle Invasive Bladder Cancer
University Of Arkansas For Medical Sciences
1 Childrens Way, Suite 653, 
Little Rock, AR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sanjay Maraboyina is a Radiation Oncologist in Little Rock, Arkansas. Dr. Maraboyina is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Pleuropulmonary Blastoma, Prostate Cancer, Familial Prostate Cancer, and Small Cell Lung Cancer (SCLC). Dr. Maraboyina is currently accepting new patients.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in AR
Hospital Affiliations
Uams Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES
1 Childrens Way, Suite 653, Little Rock, AR 72202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Radiation
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
View 8 Less Clinical Trials

17 Total Publications

Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer.
Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer.
Journal: Journal of clinical medicine
Published: May 13, 2024
Similar Doctors
Advanced in Muscle Invasive Bladder Cancer
Dr. Shahid Hameed
Radiation Oncology
Advanced in Muscle Invasive Bladder Cancer
Dr. Shahid Hameed
Radiation Oncology

Jefferson Hospital Association Inc

1600 W 40th Ave, 
Pine Bluff, AR 
 (41.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shahid Hameed is a Radiation Oncologist in Pine Bluff, Arkansas. Dr. Hameed is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Pleuropulmonary Blastoma, Breast Cancer, Prostate Cancer, and Familial Prostate Cancer. Dr. Hameed is currently accepting new patients.

Experienced in Muscle Invasive Bladder Cancer
Dr. Howard E. Morgan
Radiation Oncology
Experienced in Muscle Invasive Bladder Cancer
Dr. Howard E. Morgan
Radiation Oncology

Carti Oncology Solutions LLC

8901 Carti Way, 
Little Rock, AR 
 (4.6 miles away)
501-906-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Howard Morgan is a Radiation Oncologist in Little Rock, Arkansas. Dr. Morgan is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Metastatic Brain Tumor, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, and Pleuropulmonary Blastoma. Dr. Morgan is currently accepting new patients.

Experienced in Muscle Invasive Bladder Cancer
Dr. Michael E. May
Radiation Oncology
Experienced in Muscle Invasive Bladder Cancer
Dr. Michael E. May
Radiation Oncology

Carti Oncology Solutions LLC

8901 Carti Way, 
Little Rock, AR 
 (4.6 miles away)
501-906-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael May is a Radiation Oncologist in Little Rock, Arkansas. Dr. May is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are HER-2 Positive Breast Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Metastatic Brain Tumor. Dr. May is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Maraboyina's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile